Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Conditions
Brief summary
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib malate it works in treating patients with previously untreated metastatic kidney cancer.
Detailed description
PRIMARY OBJECTIVES: I. To determine the feasibility of intermittent sunitinib therapy in patients with metastatic renal cell carcinoma (RCC). SECONDARY OBJECTIVES: I. To determine the clinical outcome (response rate and overall progression-free survival) in metastatic renal cell carcinoma patients treated with intermittent sunitinib therapy. II. To evaluate the toxicity of intermittent sunitinib therapy in patients with metastatic renal cell carcinoma. III. To assess the feasibility of detecting circulating tumor cells (CTCs) in RCC patients and investigate the association between the VEGF -634 genotype and the occurrence of hypertension in sunitinib-treated RCC patients. OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Sunitinib dosing schedule may be changed to 14 days on followed by 7 days off, and repeated for a 6-week cycle, at the discretion of the treating physician for toxicity purposes. Cycles will be defined as 6 week intervals regardless of dosing interruptions. All patients will be treated for 4 cycles in the absence of unacceptable toxicity or RECIST-defined progressive disease.
Interventions
DRUGsunitinib malate
Given orally
Sponsors
Case Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically-proven advanced RCC with a component of clear cell histology * Measurable disease per RECIST criteria * ECOG performance status 0-1 * Prior nephrectomy is NOT required * Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase \[SGOT\]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase \[SGPT\]) ≤ 2.5 x laboratory upper limit of normal (ULN) * Total serum bilirubin ≤ 2.0 x ULN * Absolute neutrophil count (ANC) ≥ 1500/uL * Platelets ≥ 100,000/uL * Hemoglobin ≥ 8.0 g/dL (transfusion permitted) * Serum calcium ≤ 12.0 mg/dL * Serum creatinine ≤ 2.5 mg/dL * Patients with history of brain metastases can be enrolled at a minimum of 2 weeks following the completion of surgery, gamma knife or whole brain radiotherapy; repeat brain MRI not required for eligibility * Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
Exclusion criteria
* Prior systemic treatment for advanced RCC. Prior adjuvant therapy (any drug) is allowed if end of adjuvant therapy was more than 1 year prior to start of sunitinib on this protocol. * Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, severe peripheral vascular disease (claudication) or procedure on peripheral vasculature, coronary/peripheral artery bypass graft, New York Heart Association grade II or greater congestive heart failure, cerebrovascular accident or transient ischemic attack, clinically significant bleeding or pulmonary embolism * Hypertension that cannot be controlled by medications to \< 160/90 mmHg * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness * Pregnancy or breastfeeding * Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility as Assessed by Proportion of Patients Eligible for Intermittent Therapy Who Actually Receive it | after 6 months of treatment (4 cycles) | Treatment repeats every 42 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. |
Secondary
| Measure | Time frame |
|---|---|
| Change in Circulating Tumor Cells | Pre-treatment, day 1, and day 28 of every cycle |
| Relationship Between Hypertension and Germline VEGF Single Nucleotide Polymorphism (SNP) -634 Genotype | Day 28 of each cycle |
Countries
United States
Participant flow
Pre-assignment details
5 additional patients were consented but not enrolled in the study. No information was collected on them and they are not included in the patient flow. Demographics information was not collected on these patients.
Participants by arm
| Arm | Count |
|---|---|
| Arm I Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
sunitinib malate: Given orally
laboratory biomarker analysis: Correlative studies
reverse transcriptase-polymerase chain reaction: Correlative studies
polymorphism analysis: Correlative studies | 37 |
| Total | 37 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Not eligible for intermediate phase | 17 |
Baseline characteristics
| Characteristic | Arm I |
|---|---|
| Age, Customized 40-49 | 3 Participants |
| Age, Customized 50-59 | 9 Participants |
| Age, Customized 60-69 | 18 Participants |
| Age, Customized 70-79 | 6 Participants |
| Age, Customized 80-89 | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 35 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 34 Participants |
| Region of Enrollment United States | 37 participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 26 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 2 / 37 |
| other Total, other adverse events | 37 / 37 |
| serious Total, serious adverse events | 13 / 37 |
Outcome results
Primary
Feasibility as Assessed by Proportion of Patients Eligible for Intermittent Therapy Who Actually Receive it
Treatment repeats every 42 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
Time frame: after 6 months of treatment (4 cycles)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I | Feasibility as Assessed by Proportion of Patients Eligible for Intermittent Therapy Who Actually Receive it | 20 Participants |
Secondary
Change in Circulating Tumor Cells
Time frame: Pre-treatment, day 1, and day 28 of every cycle
Population: Did not complete this analysis. Data not collected.
Secondary
Relationship Between Hypertension and Germline VEGF Single Nucleotide Polymorphism (SNP) -634 Genotype
Time frame: Day 28 of each cycle
Population: Did not complete this analysis. Data not collected.